
We Work for Health Pennsylvania promotes the significant social and economic impacts of the #biopharmaceutical and #lifescience sectors in our state.
Pennsylvania
Joined July 2009
- Tweets5.7K
- Following2.9K
- Followers2.2K
- Likes5.7K
During my 12 years in the U.S. Senate, I fought to ensure the U.S. dominated the global biotech industry. I did so not only because that leadership helps save American lives & drive economic growth, but also because it’s critical for our national security. fortune.com/2026/11/12/roy-b…
11
The Trump admin just proposed sweeping new restrictions on American investments in China's biotech sector. The rules, issued under COINS, are intended to prevent U.S. capital and expertise from strengthening a strategic competitor. realclearpolicy.com/articles…
13
The Trump administration wants to keep American investment from strengthening China's technological capabilities.
But ... its latest proposal to restrict pharmaceutical investment could end up helping Beijing at America's expense. newsmax.com/sallypipes/coins…
11
What could proposed restrictions on U.S. investment in Chinese biotech mean for the 194M Americans living with chronic conditions? PFCD Chair Ken Thorpe & VP of Policy Candace DeMatteis discuss the COINS Act, its potential unintended consequences & more. youtube.com/watch?v=K1yt-LcM…
7
The Treasury Dept's proposed restrictions on U.S. investment in Chinese biotech companies could have unintended consequences for American patients seeking access to new meds. Overly broad restrictions could interfere with pharma research & development. centerfreeeconomy.org/post/n…
12
Congress has been holding hearings on pharma patents & med prices, along with U.S. Patent & Trademark Office fee-setting & oversight. During the hearings, our pharma innovators are accused of abusing the patent system when inventing & improving new meds. ipwatchdog.com/2026/10/04/wh…
8
The Trump administration just inked deals with nine more pharmaceutical companies that agreed to offer Medicaid the same low prices that foreign countries pay. In exchange, President Donald Trump promised to spare these manufacturers from tariffs. washingtonexaminer.com/op-ed…
17
Wealthy allies have been freeloading on U.S. drug innovation for years. Trump is finally doing something about it.
Grace Reilly breaks down an op-ed on the wealthy countries that let Americans fund a disproportionate share of the world's drug research. apple.co/4hOxlLh
15
About 72% of American adults are overweight or obese & roughly 12% have Type 2 diabetes. Only half of European adults are overweight or obese & just 7% have type 2 diabetes. Yet, Americans tend to survive longer than Europeans with the same disease. bit.ly/47HjzoY
1
21
Recently Pres. Trump welcomed Chinese President Xi Jinping to D.C. for the first time in a decade. Tariffs, Iran & rare earth minerals were among the issues that dominated their summit. But another arena of competition deserves D.C.’s attention: biotech. statnews.com/2026/09/30/chin…
39
For 45+ years the Bayh-Dole Act has served as the foundation of the U.S. tech transfer system & a backbone of innovation. The act has enabled & incentivized the collaboration needed to transform scientific discoveries into new tech & more. Read the report bayhdolecoalition.org/wp-con…
17
The U.S. Investments in Medical & Health Research & Development report is designed to fill a gap in industry info by providing a picture of funding across sectors. Unusual developments are accounted for in interpreting what the numbers do & don't tell us. bit.ly/3VYhD8W
19
Pres. Trump just secured 9 new pricing agreements with drug manufacturers that may help reduce what we pay for many meds, demonstrating his commitment to lowering drug prices. His dedication & desire to negotiate with companies individually is commendable. foxnews.com/opinion/trump-lo…
1
22
When President Biden signed the Inflation Reduction Act into law, his administration promised it would make prescription drugs more affordable and accessible for seniors. Yet the results tell a different story. thehill.com/opinion/healthca…
1
17
Trump's admin just launched a “Section 301” investigation into Germany’s pharma pricing practices. The move begins a process to address foreign free-riding & helps the broader goal of ensuring wealthy countries pay their fair share for global innovation. washingtonexaminer.com/op-ed…
1
26
Cancer patients in Europe face record-setting wait times when seeking cutting-edge treatment. Once European regulators approve a new oncology drug, it takes 655 days, on average, for their gov-run insurance systems to start offering it to patients. washingtonexaminer.com/op-ed…
32
In Dec. 2025, the U.K & U.S. concluded a major trade agreement in the pharma sector: a model demonstrating how a government can simultaneously improve patient access, attract investment in the life sciences & strengthen its position in a global economy. bit.ly/4yFOM7x
23
It’s been 4 yrs since Biden signed the Inflation Reduction Act into law. Back then, supporters & critics acknowledged the law’s price controls on meds would deter biotech research investments. They disagreed only about how many new drugs would be foregone. dcjournal.com/whats-the-dama…
23
For over a year, German officials have obstructed one of the Trump administration's most important reform initiatives. And the president's patience just ran out. newsweek.com/to-force-other-…
14
You’ve probably heard the expression, “all hat, no cattle.” It describes someone who wears trappings of a cowboy but has never stepped foot on a ranch. Well, the phrase also applies to some urban hospitals. gingrich360.net/p/all-hat-no…